Design, synthesis, and anti-AML activity of Hyt-based LSD1 degraders.
Lysine-specific demethylase 1 (LSD1, KDM1A) drives oncogenic progression in acute myeloid leukemia (AML) through both catalytic histone demethylation and non-catalytic scaffolding interactions with oncogenic transcription factors. Conventional LSD1 inhibitors either suffer from severe off-target toxicity or fail to blo...